| EPE129 | Acceptability of a motivational adherence intervention and point-of-care monitoring for perinatal women on ART with unsuppressed HIV viral load | E-poster | Innovations and lessons for supporting HIV prevention effective use and treatment adherence |
| EPC322 | Acceptability of an mHealth intervention to promote the use of pre-exposure prophylaxis among individuals at increased risk of HIV. The case of the Jichunge smartphone app in Dar es Salaam, Tanzania | E-poster | Measuring and enhancing retention and adherence in HIV prevention programmes |
| EPE139 | Acceptability of at-home blood sampling using volumetric absorptive microsamplers among young Black and Latinx sexual and gender minorities assigned male sex at birth in the United States | E-poster | Innovations and lessons for supporting HIV prevention effective use and treatment adherence |
| EPC318 | Acceptability of broadly neutralizing antibodies (bNAbs) for HIV prevention: a qualitative investigation among Adolescent Girls and Young Women (AGYW) in India | E-poster | Other new HIV prevention tools |
| EPD147 | Acceptability of HIV self-test among adolescent men who have sex with men and transgender women in Brazil | E-poster | Young key populations |
| EPD103 | Acceptability of injectable cabotegravir versus daily oral TDF/FTC for PrEP: lesson from HPTN 084 | E-poster | Sex workers |
| EPC224 | Acceptability of long-acting injectable prep administration by health workers in Kampala, Uganda; a cross-sectional study | E-poster | Scale up of PrEP |
| PEMOD55 | Acceptability of raltegravir granule use for neonates diagnosed with HIV at birth by healthcare workers and caregivers in Zimbabwe: A qualitative analysis | Poster exhibition | Experiences and impacts of antiretroviral therapy |
| EPD069 | Acceptability of sexual orientation disclosure interventions in primary care survey | E-poster | Gay men other men who have sex with men |
| EPE436 | Acceptability of televisits implemented during COVID-19 among adults living with HIV in Chicago | E-poster | Optimizing HIV services (prevention, testing and/or treatment) in the COVID-19 era |